Rocatinlimab

DB18809InvestigationalProtein Based Therapies

Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The... The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 4
Curator reviewed
Also known as: Anti-CD134 human monoclonal antibody (IgG1, KHK4083 dimer)
Code names: KHK-4083

Resolves to

Compound

UNIIG770V925KPCAS2431972-52-8

Targets

P43489TNFRSF4

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rocatinlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account